Modulating apolipoprotein (a) expression
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
1. A method of treating a disease or condition in a human comprising administering to the human 75 mg to 85 mg of an oligomeric compound having the following structure:
and thereby treating the disease or condition in the human.
2. The method of claim 1 , wherein about 80 mg of the oligomeric compound is administered.
3. The compound of claim 1 , wherein 80 mg of the oligomeric compound is administered.
4. The method of any of claims 1 - 3 , wherein the disease or condition is cardiovascular disease.
5. The method of claim 1 , wherein the oligomeric compound is administered as a sodium salt.
6. A method of treating a disease or condition in a human comprising administering to the human at least two separate doses of an oligomeric compound having the following structure:
wherein each separate dose comprises 75 mg to 85 mg of the oligomeric compound; and
wherein at least two doses are administered four weeks apart; and thereby treating the disease or condition in the human.
7. The method of claim 6 , wherein each dose is about 80 mg of the oligomeric compound.
8. The method of claim 6 , wherein each dose is 80 mg of the oligomeric compound.
9. The method of any of claims 6 - 8 , wherein the disease or condition is cardiovascular disease.
10. The method of claim 6 , wherein the oligomeric compound is administered as a sodium salt.